MRNA Jumps 20.1% on EPS Revision and Goldman Upgrade; VRA, WQEY, RGEN Surge
Moderna (MRNA) leads today's EPS revision screen with a 20.1% gain to $236.50 since detection on October 8, driven by a 42.9% next-year EPS growth estimate and a Goldman Sachs price target hike ahead of key melanoma data. Vera Bradley (VRA) rose 16.5% after its next-year EPS growth estimate was revised from 86.4% to 150.0%, while WISeQey (WQEY) and Repligen (RGEN) gained 14.2% and 12.4% respectively on upward estimate revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| MRNA | Healthcare | 2026-10-08 | N/A | +20.1% |
| VRA | Consumer Cyclical | 2026-10-09 | +63.6pp | +16.5% |
| WQEY | Technology | 2026-10-09 | +12.4pp | +14.2% |
| RGEN | Healthcare | 2026-10-08 | N/A | +12.4% |
| AGBK | Financial | 2026-10-08 | N/A | +11.8% |
Why did MRNA stock jump in October 2026?
Moderna (MRNA) jumped 20.1% from $197.00 to $236.50 since October 8 after analysts revised its next-year EPS growth estimate to 42.9%.
The rally accelerated on October 15 when Goldman Sachs raised its price target to $137 from $120, citing anticipation for full late-stage melanoma data for intismeran autogene due October 24 at the ESMO Congress. Positive trial data, the stock's addition to the Nasdaq-100, and reports of an NIH-backed public-private cancer vaccine initiative have reinforced momentum. The EPS revision screener flagged MRNA early, and the subsequent price action confirmed the earnings estimate upgrade as investors positioned for a catalyst-rich October.
MRNA EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: MRNA
Why did MRNA stock jump?
MRNA jumped 20.1% from $197.00 to $236.50 since October 8 after its next-year EPS growth estimate was revised upward to 42.9% and Goldman Sachs raised its price target to $137 on October 15.
Is MRNA a buy after the rally?
Goldman maintains a Neutral rating with a $137 target, implying downside from recent levels, but the upcoming ESMO melanoma data on October 24 is a key catalyst that could shift the risk-reward.
What caused MRNA's surge to 52-week highs?
The surge was driven by an upward EPS estimate revision, Goldman's price target hike, positive trial data, Nasdaq-100 inclusion, and reports of a planned NIH-backed cancer vaccine research effort.
Why did VRA stock jump in October 2026?
Vera Bradley (VRA) surged 16.5% from $5.14 to $5.99 since October 9 after its next-year EPS growth estimate was revised from 86.4% to 150.0%, a 63.6 percentage point increase.
No company-specific news was found in the window, but the magnitude of the upward revision suggests analysts are modeling a sharp earnings recovery for the consumer cyclical brand. The stock's low price and small market cap make it sensitive to estimate changes, amplifying the price move. The EPS revision screener detected VRA early, and the rally reflects the market pricing in the improved earnings outlook.
VRA EPS revision history → · Screener snapshot from 2026-10-09 →
FAQ: VRA
Why did VRA stock jump?
VRA jumped 16.5% from $5.14 to $5.99 since October 9 after its next-year EPS growth estimate was revised upward from 86.4% to 150.0%.
What caused Vera Bradley's 16% surge?
The surge was driven by a 63.6 percentage point upward revision to next-year EPS growth estimates, signaling a sharp expected earnings recovery for the consumer brand.
Is VRA a buy after the rally?
The upward EPS revision to 150.0% growth suggests improving fundamentals, but the lack of company-specific news means investors should watch for upcoming earnings for confirmation.
Why did WQEY stock jump in October 2026?
WISeQey (WQEY) rose 14.2% from $8.61 to $9.83 since October 9 after analysts raised its next-year EPS growth estimate from 34.0% to 46.3%, a 12.4 percentage point revision.
With no earnings-related news in the window, the move appears driven by sector momentum in technology and the market's response to the improved profit outlook. The upward revision signals that analysts expect accelerating earnings growth for the cybersecurity and IoT company. The EPS revision screener caught WQEY early, and the price gain reflects the market validating the estimate increase.
WQEY EPS revision history → · Screener snapshot from 2026-10-09 →
FAQ: WQEY
Why did WQEY stock jump?
WQEY jumped 14.2% from $8.61 to $9.83 since October 9 after its next-year EPS growth estimate was revised upward from 34.0% to 46.3%.
What is WQEY's EPS growth estimate?
WQEY's next-year EPS growth estimate is 46.3%, up from 34.0% before the revision, reflecting a 12.4 percentage point increase.
Is WQEY a buy after the rally?
The upward EPS revision to 46.3% growth is a positive signal, though the lack of recent news means investors should monitor for upcoming earnings or contract announcements.
Why did RGEN stock jump in October 2026?
Repligen (RGEN) climbed 12.4% from $163.84 to $184.17 since October 8 after analysts reaffirmed a 27.9% next-year EPS growth estimate, which the screener flagged as a positive revision.
The company announced on October 13 that it will report third-quarter 2026 financial results on October 27, giving investors a near-term catalyst. As a bioprocessing technology provider, Repligen benefits from broader strength in the life sciences tools sector and rising demand for biologic drug manufacturing. The EPS revision screener detected RGEN early, and the subsequent price gain shows the market endorsing the stable earnings outlook.
RGEN EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: RGEN
Why did RGEN stock jump?
RGEN jumped 12.4% from $163.84 to $184.17 since October 8 after analysts reaffirmed a 27.9% next-year EPS growth estimate and the company set its Q3 earnings date for October 27.
What is RGEN's EPS growth estimate?
Repligen's next-year EPS growth estimate is 27.9%, which was flagged by the EPS revision screener as a positive signal.
When does RGEN report earnings?
Repligen will report third-quarter 2026 financial results on October 27, 2026, before the market opens, with a conference call at 8:00 a.m. ET.
Why did AGBK stock jump in October 2026?
AGI Inc (AGBK) gained 11.8% from $6.51 to $7.28 since October 8 after analysts raised its next-year EPS growth estimate to 44.5%.
No earnings-related news was found in the window, but the upward revision in the financial sector suggests improving profitability expectations, potentially driven by favorable interest rate dynamics or credit conditions. The stock's rally reflects the market pricing in the higher earnings growth forecast. The EPS revision screener identified AGBK early, and the price action confirms the estimate upgrade.
AGBK EPS revision history → · Screener snapshot from 2026-10-08 →
FAQ: AGBK
Why did AGBK stock jump?
AGBK jumped 11.8% from $6.51 to $7.28 since October 8 after its next-year EPS growth estimate was revised upward to 44.5%.
What is AGBK's EPS growth estimate?
AGI Inc's next-year EPS growth estimate is 44.5%, which was flagged by the EPS revision screener as a positive revision.
Is AGBK a buy after the rally?
The upward EPS revision to 44.5% growth is a bullish signal, but without company-specific news, investors should look for upcoming financial reports to confirm the trend.
Today's top performers highlight the market's strong reaction to upward EPS estimate revisions, particularly in healthcare and technology, where MRNA's 20.1% gain on a 42.9% growth estimate and Goldman upgrade led the pack. The broad-based gains across sectors suggest investors are rewarding companies with improving earnings outlooks amid a mixed macro backdrop.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →